Testmate Health Raised $6M in Seed Funding to Launch Revolutionary At-Home STI Diagnostic Test

Testmate Health Raised $6M in Seed Funding to Launch Revolutionary At-Home STI Diagnostic Test

Test Meet HealthA trailblazer in home testing solutions, has raised $6 million to introduce the world's first low-cost, over-the-counter (OTC) self-test for sexually transmitted infections (STIs), chlamydia and Gonorrhea

The current testing process for these common infections in the United States typically involves a visit to a clinic and days of waiting for results. Testmate Health aims to revolutionize this approach with a simple urine test designed to provide lab-quality results in the comfort of your own home in less than 30 minutes.

Dr. Seo-Vena Sahi, founder and CEO of TestMate Health, brings expertise in sexual health diagnostics, with her research at the World Health Organization highlighting the need for affordable and accurate STI tests. Leveraging a revolutionary urine-based DNA platform detection technology, Testmate aims to empower individuals to take charge of their sexual health with an accessible, accurate and convenient self-testing solution.

The seed funding round, led by RH Capital and supported by The Helm, Zürcher Kantonal Bank, Amboy Street Ventures, Lichtsteiner Foundation, and Dartlabs.io, will accelerate Testmate's product development and market validation efforts. Dr. Sahi emphasizes the company's commitment to tackling the silent epidemic of STIs, particularly chlamydia and gonorrhea, through innovative and affordable testing solutions.

Elizabeth Bailey, lead investor at RH Capital, recognizes the critical need for healthcare to address the test-mate's at-home STI testing approach, while maintaining the highest standards of accuracy and confidentiality. Emphasizes the importance of improving access to essential diagnostics.

About the Author

Leave a Reply